Base de dados : MEDLINE
Pesquisa : D06.472.699.322.326 [Categoria DeCS]
Referências encontradas : 25648 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2565 ir para página                         

  1 / 25648 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29413576
[Au] Autor:Rosting C; Tran EV; Gjelstad A; Halvorsen TG
[Ad] Endereço:Department of Pharmaceutical Chemistry, School of Pharmacy, University of Oslo, P.O. Box 1068, Blindern, 0316 Oslo, Norway. Electronic address: Cecilie.rosting@farmasi.uio.no.
[Ti] Título:Determination of the low-abundant protein biomarker hCG from dried matrix spots using immunocapture and nano liquid chromatography mass spectrometry.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;1077-1078:44-51, 2018 Mar 01.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Using LC-MS/MS for determination of low-abundance protein biomarkers from dried blood spots is challenging due to the combination of low biomarker levels (low pM-level) and small sample volumes (typically <50 µL). In the present paper it is demonstrated that use of state-of-the-art nano liquid chromatography triple quadrupole mass spectrometry in combination with immunoaffinity sample clean-up enable determination of the low abundance biomarker human chorionic gonadotropin (hCG) from four different biological matrices (whole blood, serum, plasma and urine) at its upper reference level (low pM). Detection limits for hCG was determined for all matrices from both commercially available non-soluble DBS sampling material (DMPK-C) and the water-soluble material carboxymethyl cellulose (CMC). The detection limits (S/N = 3) were ranging from 5.0 IU/L (14.5 pM; whole blood) to 10.5 IU/L (30.5 pM; urine) for DMPK-C and from 2.1 IU/L (6.1 pM; urine) to 6.4 IU/L (18.6 pM; plasma) for CMC. A brief evaluation was performed for both sampling materials using serum as matrix resulting in sufficient linearity (r ≥ 0.93, range 20-1000 IU/mL (58-2900 pM) for DMPK-C and 10-1000 IU/mL (29-2900 pM) for CMC), repeatability (RSD% = 13-31%) and accuracy (95-106%). To demonstrate the applicability of the method to real samples, a serum sample from a patient previously diagnosed with cancer was also analyzed using both sampling materials. The concentration levels found using the two materials were similar (5280±â€¯595 IU/L (15,312 ±â€¯1726 pM, n = 3) in the DMPK-C spot and 5060 ±â€¯430 IU/L (14,674 ±â€¯1247 pM, n = 3) in the CMC spot). All in all this demonstrated that the tools for determination of low abundance biomarkers at upper reference level from dried matrix spots now is available through a combination of immunoaffinity enrichment and state-of-the-art LC-MS/MS.
[Mh] Termos MeSH primário: Gonadotropina Coriônica/sangue
Cromatografia Líquida/métodos
Teste em Amostras de Sangue Seco/métodos
Espectrometria de Massas em Tandem/métodos
[Mh] Termos MeSH secundário: Seres Humanos
Limite de Detecção
Modelos Lineares
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chorionic Gonadotropin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180208
[St] Status:MEDLINE


  2 / 25648 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29384854
[Au] Autor:Gao J; Li X; Chen J; Gong W; Yue K; Wu Z
[Ad] Endereço:Department of Interventional Radiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
[Ti] Título:Uterine artery embolization combined with local infusion of methotrexate and 5- fluorouracil in treating ectopic pregnancy: A CONSORT-compliant article.
[So] Source:Medicine (Baltimore);97(5):e9722, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: To compare the efficiency and safety of uterine artery embolization (UAE) combined with local infusion of methotrexate (MTX) or MTX and 5-fluorouracil (5-FU) in the treatment of ectopic pregnancy (EP). METHODS: One hundred women with EP were prospectively enrolled from December 2012 to February 2015 and randomly allocated into 2 groups. One group was treated with UAE combined MTX, and the other with UAE combined with MTX and 5-FU. Local MTX was administrated at a dose of 80 to 120 mg, based on the initial ß-human chorionic gonadotropin (ß-HCG) levels, and 5-FU was given intra-arterially at a uniform dose of 0.5 g. RESULTS: Bilateral UAE was successfully performed in all 100 patients, 88 of whom were clinically successfully treated, 45 (91.8%) in the MTX group, and 43 (87.8%) in the MTX + 5-FU group; 89% of the patients achieved normalization of ß-HCG below 70,000 mIU/mL within 14 to 21 days postoperatively. The time to successful ß-HCG resolution was 26.74 ±â€Š5.57 days for patients receiving MTX + UAE treatment, and 27.57 ±â€Š5.08 days for those treated with additional 5-FU. Six patients had subsequent intramuscular injections of MTX and 6 had a unilateral salpingectomy after the treatment failure. Mild immediate side effects accounted for 24.5% in the sole MTX and 58.3% in MTX + 5-FU group. CONCLUSION: A combination of UAE and intrauterine infusion of MTX showed comparable efficiency to UAE combined with a local infusion of MTX and 5-FU in treating EP patients with the intention to preserve fertility.
[Mh] Termos MeSH primário: Abortivos/uso terapêutico
Fluoruracila/administração & dosagem
Metotrexato/administração & dosagem
Gravidez Ectópica/tratamento farmacológico
Gravidez Ectópica/cirurgia
Embolização da Artéria Uterina
[Mh] Termos MeSH secundário: Adulto
Antimetabólitos/uso terapêutico
Gonadotropina Coriônica/metabolismo
Terapia Combinada
Feminino
Antagonistas do Ácido Fólico/uso terapêutico
Seres Humanos
Injeções Intra-Arteriais
Gravidez
Gravidez Ectópica/metabolismo
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Abortifacient Agents); 0 (Antimetabolites); 0 (Chorionic Gonadotropin); 0 (Folic Acid Antagonists); U3P01618RT (Fluorouracil); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009722


  3 / 25648 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390471
[Au] Autor:Niu G; Yuan LJ; Gong FQ; Yang J; Zhu CX; Shen HW
[Ad] Endereço:Department of Gynecology and Obstetrics.
[Ti] Título:Early pregnancy following multidrug regimen chemotherapy in a gestational trophoblastic neoplasia patient: A case report.
[So] Source:Medicine (Baltimore);96(51):e9221, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Gestational trophoblastic neoplasia is a group of rare tumors that can be cured using chemotherapy. The use of artificial contraception for at least 1 year is recommended not only due to the high recurrence rate in the first year after treatment, but also because of the unclear genetic toxic effects of multidrug regimen chemotherapy on reproductive cells. There is no consensus about the contraception duration, but most patients want to have children. PATIENT CONCERNS: This case involved a 33-year-old female suffering from gestational trophoblastic neoplasia and 5-fluorouracil + actinomycin-D chemotherapy. She became pregnant 1 month after finishing the chemotherapy. DIAGNOSIS: Gestational trophoblastic neoplasia. INTERVENTIONS: No treatment during pregnancy. OUTCOMES: The patient had a full-term normal delivery, and the baby showed normal development and growth after a follow-up of 48 months. LESSONS: Pregnancy soon after chemotherapy can be viable with rigorous prenatal care.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Doença Trofoblástica Gestacional/tratamento farmacológico
Complicações Neoplásicas na Gravidez/tratamento farmacológico
Resultado da Gravidez
[Mh] Termos MeSH secundário: Adulto
Gonadotropina Coriônica/sangue
Dactinomicina/administração & dosagem
Relação Dose-Resposta a Droga
Esquema de Medicação
Feminino
Desenvolvimento Fetal/fisiologia
Fluoruracila/administração & dosagem
Idade Gestacional
Doença Trofoblástica Gestacional/diagnóstico
Seres Humanos
Saúde do Lactente
Recém-Nascido
Masculino
Gravidez
Complicações Neoplásicas na Gravidez/diagnóstico
Cuidado Pré-Natal/métodos
Nascimento a Termo
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Chorionic Gonadotropin); 1CC1JFE158 (Dactinomycin); U3P01618RT (Fluorouracil)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009221


  4 / 25648 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29331479
[Au] Autor:Zhao C; Zhu W; Yin S; Cao Q; Zhang H; Wen X; Zhang G; Xie W; Chen S
[Ad] Endereço:College of Life Sciences, Key Laboratory of Biodiversity and Biotechnology of Jiangsu Province, Nanjing Normal University, Nanjing, Jiangsu 210023, China; Co-Innovation Center for Marine Bio-Industry Technology of Jiangsu Province, Lianyungang, Jiangsu 222005, China.
[Ti] Título:Molecular characterization and expression of Piwil1 and Piwil2 during gonadal development and treatment with HCG and LHRH-A in Odontobutis potamophila.
[So] Source:Gene;647:181-191, 2018 Mar 20.
[Is] ISSN:1879-0038
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Piwi proteins play an important regulatory role in germ cell division during gametogenesis and gonad development. In order to understand the function of Piwi genes in the reproductive process of the dark sleeper, we identified and characterized Piwil1 and Piwil2 from gonad tissue. The tissue distribution demonstrated that Piwils were highly expressed in the gonad of the dark sleeper. During gonad development, higher expression was observed in stage I of both the testes and ovaries than in subsequent stages at mRNA and protein levels. The results of immunohistochemistry demonstrated that Piwils were predominantly distributed in the spermatogonia, spermatocytes, and early oocytes. When treated with the HPG axis hormone (HCG and LHRH-A2), the expression of Piwils was significantly decreased in the testes and ovaries at mRNA and protein levels. All of these results indicated that Piwils play a vital role in gonad development and gametogenesis. Our findings provide valuable evidence to further clarify the underlying modulation mechanism of Piwils in teleosts.
[Mh] Termos MeSH primário: Proteínas Argonauta/genética
Gonadotropina Coriônica/farmacologia
Regulação da Expressão Gênica no Desenvolvimento/genética
Hormônio Liberador de Gonadotropina/farmacologia
Gônadas/efeitos dos fármacos
Perciformes/genética
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Animais
Sequência de Bases
Gametogênese/efeitos dos fármacos
Gametogênese/genética
Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos
Masculino
Oócitos/efeitos dos fármacos
Filogenia
RNA Mensageiro/genética
Espermatócitos/efeitos dos fármacos
Espermatogônias/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Argonaute Proteins); 0 (Chorionic Gonadotropin); 0 (RNA, Messenger); 33515-09-2 (Gonadotropin-Releasing Hormone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180115
[St] Status:MEDLINE


  5 / 25648 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29309424
[Au] Autor:Jacinto MJ; Trabuco JRC; Vu BV; Garvey G; Khodadady M; Azevedo AM; Aires-Barros MR; Chang L; Kourentzi K; Litvinov D; Willson RC
[Ad] Endereço:iBB-Institute for Bioengineering and Biosciences, Department of Bioengineering, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal.
[Ti] Título:Enhancement of lateral flow assay performance by electromagnetic relocation of reporter particles.
[So] Source:PLoS One;13(1):e0186782, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Lateral flow assays (LFAs) are a widely-used point-of care diagnostic format, but suffer from limited analytical sensitivity, especially when read by eye. It has recently been reported that LFA performance can be improved by using magnetic reporter particles and an external magnetic field applied at the test line. The mechanism of sensitivity/performance enhancement was suggested to be concentration/retardation of reporter particles at the test line. Here we demonstrate an additional mechanism of particle relocation where reporter particles from the lower depths of the translucent LFA strip relocate to more-visible locations nearer to the top surface, producing a more visible signal. With a magnetic field we observed an improvement in sensitivity of human chorionic gonadotropin (hCG) detection from 1.25 ng/mL to 0.31 ng/mL. We also observed an increase of the color intensity per particle in test lines when the magnetic field was present.
[Mh] Termos MeSH primário: Campos Eletromagnéticos
[Mh] Termos MeSH secundário: Anticorpos/imunologia
Gonadotropina Coriônica/análise
Gonadotropina Coriônica/imunologia
Limite de Detecção
Soroalbumina Bovina/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies); 0 (Chorionic Gonadotropin); 27432CM55Q (Serum Albumin, Bovine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180109
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0186782


  6 / 25648 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452938
[Au] Autor:Casarini L; Riccetti L; De Pascali F; Gilioli L; Marino M; Vecchi E; Morini D; Nicoli A; La Sala GB; Simoni M
[Ad] Endereço:Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, NOCSAE, via P. Giardini 1355, 41126 Modena, Italy. livio.casarini@unimore.it.
[Ti] Título:Estrogen Modulates Specific Life and Death Signals Induced by LH and hCG in Human Primary Granulosa Cells In Vitro.
[So] Source:Int J Mol Sci;18(5), 2017 Apr 28.
[Is] ISSN:1422-0067
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Luteinizing hormone (LH) and human chorionic gonadotropin (hCG) are glycoprotein hormones used for assisted reproduction acting on the same receptor (LHCGR) and mediating different intracellular signaling. We evaluated the pro- and anti-apoptotic effect of 100 pM LH or hCG, in the presence or in the absence of 200 pg/mL 17ß-estradiol, in long-term, serum-starved human primary granulosa cells (hGLC) and a transfected granulosa cell line overexpressing LHCGR (hGL5/LHCGR). To this purpose, phospho-extracellular-regulated kinase 1/2 (pERK1/2), protein kinase B (pAKT), cAMP-responsive element binding protein (pCREB) activation and procaspase 3 cleavage were evaluated over three days by Western blotting, along with the expression of target genes by real-time PCR and cell viability by colorimetric assay. We found that LH induced predominant pERK1/2 and pAKT activation , and anti-apoptotic gene expression, while hCG mediated more potent CREB phosphorylation, expression of and procaspase 3 cleavage than LH. Cell treatment by LH is accompanied by increased (serum-starved) cell viability, while hCG decreased the number of viable cells. The hCG-specific, pro-apoptotic effect was blocked by a physiological dose of 17ß-estradiol, resulting in pAKT activation, lack of procaspase 3 cleavage and increased cell viability. These results confirm that relatively high levels of steroidogenic pathway activation are linked to pro-apoptotic signals in vitro, which may be counteracted by other factors, i.e., estrogens.
[Mh] Termos MeSH primário: Gonadotropina Coriônica/farmacologia
Estradiol/farmacologia
Hormônio Luteinizante/farmacologia
Transdução de Sinais/efeitos dos fármacos
[Mh] Termos MeSH secundário: Aromatase/metabolismo
Proteína de Ligação a CREB/metabolismo
Caspase 3/genética
Caspase 3/metabolismo
Sobrevivência Celular/efeitos dos fármacos
Células Cultivadas
Feminino
Expressão Gênica/efeitos dos fármacos
Células da Granulosa/citologia
Células da Granulosa/efeitos dos fármacos
Células da Granulosa/metabolismo
Seres Humanos
Proteína Quinase 1 Ativada por Mitógeno/metabolismo
Proteína Quinase 3 Ativada por Mitógeno/metabolismo
Fosforilação/efeitos dos fármacos
Proteínas Proto-Oncogênicas c-akt/metabolismo
Proteína Supressora de Tumor p53/genética
Proteína Supressora de Tumor p53/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chorionic Gonadotropin); 0 (Tumor Suppressor Protein p53); 4TI98Z838E (Estradiol); 9002-67-9 (Luteinizing Hormone); EC 1.14.14.1 (Aromatase); EC 1.14.14.1 (CYP19A1 protein, human); EC 2.3.1.48 (CREB-Binding Protein); EC 2.7.11.1 (Proto-Oncogene Proteins c-akt); EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1); EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3); EC 3.4.22.- (Caspase 3)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180122
[Lr] Data última revisão:
180122
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  7 / 25648 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29202975
[Au] Autor:Bishop LA; Richter KS; Patounakis G; Andriani L; Moon K; Devine K
[Ad] Endereço:Shady Grove Fertility, Rockville, Maryland. Electronic address: lauren.bishop@nih.gov.
[Ti] Título:Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss in younger in vitro fertilization patients.
[So] Source:Fertil Steril;108(6):980-987, 2017 Dec.
[Is] ISSN:1556-5653
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To assess the relationship between diminished ovarian reserve and pregnancy outcomes in a large cohort of women achieving pregnancy through in vitro fertilization (IVF). We evaluated antral follicle count (AFC) and baseline FSH as a measure of ovarian reserve. Secondarily, we assessed whether diminished ovarian reserve was associated with aneuploidy among spontaneous abortions. DESIGN: Retrospective cohort study. SETTING: Multicenter private practice. PATIENT(S): All patients aged 21-44 years undergoing fresh autologous IVF cycles during 2009-2013 that resulted in positive serum hCG with recorded baseline FSH levels. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Live births per early pregnancy, biochemical pregnancies, clinical pregnancy losses, and aneuploidy rates in products of conception among pregnancy losses. RESULT(S): A total of 9,489 cycles among 8,214 patients were analyzed. There was no association between live birth and ovarian reserve among pregnant IVF patients under the age of 35 years. Among patients 35 years of age and older, elevated baseline FSH was associated with a higher risk of pregnancy loss, which increased with increasing age. AFC was not significantly associated with pregnancy loss at any age. No associations were found between ovarian reserve measures and aneuploidy in products of conception in age-adjusted analyses, although the power to effectively evaluate this was limited. CONCLUSION(S): Diminished ovarian reserve is not associated with an increase in miscarriage among younger women achieving pregnancy through IVF. Elevated FSH is associated with a higher risk of IVF pregnancy loss among older patients. We found no evidence to confirm that diminished ovarian reserve is associated with increased aneuploidy among spontaneous abortions.
[Mh] Termos MeSH primário: Aborto Espontâneo/etiologia
Fertilização In Vitro/efeitos adversos
Hormônio Foliculoestimulante Humano/sangue
Infertilidade Feminina/terapia
Reserva Ovariana
Insuficiência Ovariana Primária/diagnóstico
[Mh] Termos MeSH secundário: Aborto Espontâneo/genética
Adulto
Fatores Etários
Aneuploidia
Biomarcadores/sangue
Distribuição de Qui-Quadrado
Gonadotropina Coriônica/sangue
Feminino
Seres Humanos
Infertilidade Feminina/diagnóstico
Infertilidade Feminina/etiologia
Infertilidade Feminina/fisiopatologia
Nascimento Vivo
Análise Multivariada
Folículo Ovariano
Gravidez
Taxa de Gravidez
Insuficiência Ovariana Primária/sangue
Insuficiência Ovariana Primária/complicações
Insuficiência Ovariana Primária/fisiopatologia
Estudos Retrospectivos
Fatores de Risco
Resultado do Tratamento
Estados Unidos
Regulação para Cima
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Biomarkers); 0 (Chorionic Gonadotropin); 0 (Follicle Stimulating Hormone, Human)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171215
[Lr] Data última revisão:
171215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE


  8 / 25648 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Maestá, Izildinha
Texto completo
[PMID]:28927899
[Au] Autor:Dantas PRS; Maestá I; Filho JR; Junior JA; Elias KM; Howoritz N; Braga A; Berkowitz RS
[Ad] Endereço:Department of Gynecology and Obstetrics, Botucatu Medical School, Postgraduate Program of Gynecology, Obstetrics and Mastology of São Paulo State University. Rubião Júnior District, Botucatu, São Paulo, Brazil; Rio de Janeiro Trophoblastic Disease Center, Brazilian Association of Gestational Trophob
[Ti] Título:Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors?
[So] Source:Gynecol Oncol;147(2):364-370, 2017 Nov.
[Is] ISSN:1095-6859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the influence of hormonal contraception (HC) on the development and clinical aggressiveness of gestational trophoblastic neoplasia (GTN) and the time for normalization of human chorionic gonadotropin (hCG) levels. METHODS: A retrospective cohort study was conducted with women diagnosed with molar pregnancy, followed at the Rio de Janeiro Trophoblastic Disease Center, between January 2005 and January 2015. The occurrence of postmolar GTN and the time for hCG normalization between users of HC or barrier methods (BM) during the postmolar follow-up or GTN treatment were evaluated. RESULTS: Among 2828 patients included in this study, 2680 (95%) used HC and 148 (5%) used BM. The use of HC did not significantly influence the occurrence of GTN (ORa: 0.66, 95% CI: 0.24-1.12, p=0.060), despite different formulations: progesterone-only (ORa: 0.54, 95% CI: 0.29-1.01, p=0.060) or combined oral contraception (COC) (ORa: 0.50, 95% CI: 0.27-1.01, p=0.60) or with different dosages of ethinyl estradiol: 15mcg (ORa, 1.33, 95% CI 0.79-2.24, p=0.288), 20mcg (ORa: 1.02, 95% CI: 0.64-1.65, p=0.901), 30mcg (ORa: 1.17, 95% CI: 0.78-1.75, p=0.437) or 35mcg (ORa: 0.77, 95% CI: 0.42-1.39, p=0.386). Time to hCG normalization ≥10weeks (ORa: 0.58, 95% CI: 0.43-1.08, p=0.071) or time to remission with chemotherapy≥14weeks (ORa: 0.60, 95% CI: 0.43-1.09, p=0.067) did not significantly differ among HC users when compared to patients using BM, when controlling for other risk factors using multivariate logistic regression. CONCLUSIONS: The use of HC during postmolar follow-up or GTN treatment does not seem to increase the risk of GTN or its severity and does not postpone the normalization of hCG levels.
[Mh] Termos MeSH primário: Anticoncepcionais Orais Hormonais/administração & dosagem
Doença Trofoblástica Gestacional/epidemiologia
Mola Hidatiforme/terapia
[Mh] Termos MeSH secundário: Adulto
Gonadotropina Coriônica/sangue
Estudos de Coortes
Dispositivos Anticoncepcionais Femininos
Anticoncepcionais Orais Hormonais/efeitos adversos
Feminino
Seguimentos
Doença Trofoblástica Gestacional/sangue
Doença Trofoblástica Gestacional/etiologia
Doença Trofoblástica Gestacional/patologia
Seres Humanos
Mola Hidatiforme/sangue
Mola Hidatiforme/cirurgia
Gravidez
Estudos Retrospectivos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chorionic Gonadotropin); 0 (Contraceptives, Oral, Hormonal)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170921
[St] Status:MEDLINE


  9 / 25648 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28911134
[Au] Autor:Korevaar TIM; Steegers EAP; Chaker L; Medici M; Jaddoe VWV; Visser TJ; de Rijke YB; Peeters RP
[Ad] Endereço:The Generation R Study Group, Erasmus Medical Center and/or Sophia Children's Hospital, 3015 GE Rotterdam, The Netherlands.
[Ti] Título:Thyroid Function and Premature Delivery in TPO Antibody-Negative Women: The Added Value of hCG.
[So] Source:J Clin Endocrinol Metab;102(9):3360-3367, 2017 Sep 01.
[Is] ISSN:1945-7197
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Context: Human chorionic gonadotropin (hCG) stimulates thyroid function during pregnancy. We recently showed that thyroid autoimmunity severely attenuated the thyroidal response to hCG stimulation and that this may underlie the higher risk of premature delivery in thyroperoxidase antibody (TPOAb)-positive women. We hypothesized that a lower thyroidal response to hCG stimulation in TPOAb-negative women is also associated with a higher risk of premature delivery and preterm premature rupture of membranes (pPROM). Design, Setting, and Participants: Thyrotropin (TSH), free thyroxine (FT4), and hCG concentrations were available in 5644 TPOAb-negative women from a prospective cohort. We tested for interaction between TSH or FT4 and hCG in linear regression models for duration of pregnancy and logistic regression models for premature delivery/pPROM. Accordingly, analyses were stratified per TSH percentile (TSH ≥ 85th percentile) and hCG per 10,000 IU/L. Results: Women with high TSH and low hCG concentrations did not have a higher risk of premature delivery or pPROM, with protective effect estimates. In contrast, women with a high TSH concentration despite a high hCG concentration had twofold to 10-fold higher risk of premature delivery (Pdifference = 0.022) and an up to fourfold higher risk of pPROM (Pdifference = 0.079). hCG concentrations were not associated with premature delivery or pPROM. Conclusion: In TPOAb-negative women with high-normal TSH concentrations, only women with high hCG concentrations had a higher risk of premature delivery or pPROM. These results suggest a lower thyroidal response to hCG stimulation is also associated with premature delivery in TPOAb-negative women and that an additional measurement of hCG may improve thyroid-related risk assessments during pregnancy.
[Mh] Termos MeSH primário: Autoantígenos/imunologia
Gonadotropina Coriônica/sangue
Iodeto Peroxidase/imunologia
Proteínas de Ligação ao Ferro/imunologia
Resultado da Gravidez
Nascimento Prematuro/imunologia
Tireotropina/sangue
[Mh] Termos MeSH secundário: Adulto
Biomarcadores/sangue
Estudos de Coortes
Feminino
Idade Gestacional
Seres Humanos
Gravidez
Estudos Prospectivos
Medição de Risco
Testes de Função Tireóidea
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Autoantigens); 0 (Biomarkers); 0 (Chorionic Gonadotropin); 0 (Iron-Binding Proteins); 9002-71-5 (Thyrotropin); EC 1.11.1.7 (TPO protein, human); EC 1.11.1.8 (Iodide Peroxidase)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170916
[St] Status:MEDLINE
[do] DOI:10.1210/jc.2017-00846


  10 / 25648 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28791818
[Au] Autor:Litwinska E; Litwinska M; Oszukowski P; Szaflik K; Kaczmarek P
[Ad] Endereço:Perinatology and Gynecology Department, Polish Mother's Memorial Hospital Research Institute, Lódz, Poland.
[Ti] Título:Combined screening for early and late pre-eclampsia and intrauterine growth restriction by maternal history, uterine artery Doppler, mean arterial pressure and biochemical markers.
[So] Source:Adv Clin Exp Med;26(3):439-448, 2017 May-Jun.
[Is] ISSN:1899-5276
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Pre-eclampsia is a systemic disease connected with high maternal and fetal morbidity and mortality. Despite significant progress achieved in perinatal medicine, pre-eclampsia is still one of the most significant current problems in obstetrics. OBJECTIVES: The aim of the study was to establish diagnostic algorithms for early and late pre-eclampsia (PE) and intrauterine growth restriction (IUGR). MATERIAL AND METHODS: A total of 320 pregnant women between 11 + 0 and 13 + 6 weeks of gestation were recruited for a case-control study. The study group consisted of 22 patients with early PE, 29 patients with late PE and 269 unaffected controls. The following parameters were recorded: maternal history, mean arterial pressure (MAP), mean uterine artery pulsatility index (UtA-PI), and the concentrations of placental growth factor (PlGF), pregnancy-associated plasma protein A (PAPP-A) and free beta-human chorionic gonadotropin (free ß-hCG). RESULTS: A multivariable stepwise logistic regression analysis indicated that the best screening model for the prediction of early PE is based on a combined analysis of maternal risk factors, UtA-PI and PlGF levels (sensitivity: 91%; specificity: 84%). The best screening model for the prediction of late PE is based on a combined analysis of maternal risk factors, UtA-PI and MAP (sensitivity: 85%; specificity: 83%). The most effective screening model for the prediction of IUGR is based on a combined analysis of maternal risk factors, UtA-PI and PlGF concentrations (sensitivity: 91%; specificity: 83%). CONCLUSIONS: The integrated model of screening established in this study can be a valuable method to identify patients at increased risk of developing pre-eclampsia and related complications. The ability to predict the occurrence of pre-eclampsia in early pregnancy would enable maternal and fetal morbidity to be reduced through the introduction of strict obstetric surveillance as well as planned delivery in a reference center.
[Mh] Termos MeSH primário: Pressão Arterial/fisiologia
Biomarcadores/sangue
Retardo do Crescimento Fetal/sangue
Retardo do Crescimento Fetal/diagnóstico
Pré-Eclâmpsia/sangue
Pré-Eclâmpsia/diagnóstico
Artéria Uterina/metabolismo
[Mh] Termos MeSH secundário: Adulto
Estudos de Casos e Controles
Gonadotropina Coriônica/sangue
Feminino
Retardo do Crescimento Fetal/metabolismo
Idade Gestacional
Seres Humanos
Fator de Crescimento Placentário/sangue
Pré-Eclâmpsia/metabolismo
Gravidez
Proteína Plasmática A Associada à Gravidez/metabolismo
Fatores de Risco
Ultrassonografia Pré-Natal/métodos
Útero/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Chorionic Gonadotropin); 144589-93-5 (Placenta Growth Factor); EC 3.4.24.- (Pregnancy-Associated Plasma Protein-A)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170810
[St] Status:MEDLINE
[do] DOI:10.17219/acem/62214



página 1 de 2565 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde